Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Receivables - Net: 2019-2025

Historic Receivables - Net for Seres Therapeutics (MCRB) over the last 3 years, with Sep 2025 value amounting to $351,000.

  • Seres Therapeutics' Receivables - Net was N/A to $351,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $351,000, marking a year-over-year change of. This contributed to the annual value of $9.4 million for FY2020, which is 425.88% up from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Receivables - Net is $351,000, which was down 95.26% from $7.4 million recorded in Q1 2025.
  • In the past 5 years, Seres Therapeutics' Receivables - Net registered a high of $7.4 million during Q1 2025, and its lowest value of $351,000 during Q3 2025.
  • Over the past 1 years, Seres Therapeutics' median Receivables - Net value was $3.9 million (recorded in 2025), while the average stood at $3.9 million.
  • Within the past 5 years, the most significant YoY rise in Seres Therapeutics' Receivables - Net was 24.95% (2021), while the steepest drop was 63.16% (2021).
  • Quarterly analysis of 2 years shows Seres Therapeutics' Receivables - Net stood at $1.2 million in 2021, then followed by $351,000 in 2025.
  • Its last three reported values are $351,000 in Q3 2025, $7.4 million for Q1 2025, and $1.2 million during Q3 2021.